During World War II, with the absence of imports, these plants are the sole source of pharmaceutical supplies for the local market and neighboring countries.

Teva begins trading on the Tel Aviv Stock Exchange (TASE) as the Teva Middle East Pharmaceutical Chemical Works Company Ltd.

Teva, Assia, and Zori unite to create Israel’s largest drug maker - Teva Pharmaceutical Industries Ltd.

Eli Hurvitz becomes first CEO of the merged company.  Mr. Hurvitz, the beloved and highly respected leader, served as President and CEO in the years 1976-2002, and as Chairman of the Board from 2002-2010.

Photo credit: Moshe Shai

Teva takes its first step abroad into Europe with the acquisition of Orphahell in the Netherlands.

The Kfar Saba manufacturing facility is granted approval by the FDA in 1982.

Teva shares are registered for trading on NASDAQ.

US Hatch-Waxman Act is passed, enabling Teva’s entry into generic medicines in the 1990s.

Teva expands its US market share through a joint venture with W.R. Grace, and the acquisition of Lemmon facilitates Teva’s entry into the US market.

Teva acquires Abic, the second largest pharmaceutical company in Israel, and completes the acquisition of Israeli API producer Plantex Ltd.

Acquisition of GRYPharm - Germany.

Teva opens its flagship Teva-Tech API production facility at Ramat Hovav in Israel’s Negev desert.

Acquisition of APS/Berk in the UK marks Teva’s first entry into a major Western European market.

Teva’s innovative treatment for multiple sclerosis (MS), and the first specialty medicine for the company, is approved by the FDA.

Acquisition of Novopharm Ltd, the second largest producer of generics in Canada, and its Hungarian subsidiary Human. Teva becomes the largest generic pharmaceutical company in North America.

Teva’s innovative treatment for multiple sclerosis receives European Union approval.

Acquisition of Regent Drugs Limited in India (renamed Teva API India Ltd.), which joins Teva’s API division.

Acquisition of Sicor Inc. and its subsidiaries, bringing together Teva's successful oral dose generic drugs franchise with Sicor's leading generic injectable business, API and biogenerics capabilities.

Teva's innovative drug for the treatment of Parkinson’s disease is approved for marketing in Israel and the EU. The treatment is later approved by the FDA in 2006.

Acquisition of IVAX Corporation in the US strengthens Teva’s worldwide presence through subsidiaries in Europe, Latin America and the Far East. The acquisition brings Teva a rich pipeline of generic and proprietary products in the complementary areas of respiratory, CNS, and oncology.

Acquisition of Barr Pharmaceuticals in the US, including subsidiary PLIVA in Europe, enhances Teva’s leadership position in the US and key global markets, and strengthens Teva's portfolio and pipeline.

Joint venture with Japan-based Kowa Company, Ltd.  positions Teva to supply generic pharmaceutical products to the Japanese market.

Acquisition of Germany’s ratiopharm significantly increases Teva's market share in Europe, harnessing ratiopharm's excellent foundation for biosimilars, branded generics and tenders.

Acquisition of Cephalon and its global subsidiaries strengthens Teva’s therapeutic diversification while providing a leadership position in branded and specialty pharmaceuticals

Teva begins trading on the NYSE (New York Stock Exchange).

Joint venture with Handok provides Teva with entrance into the South Korean pharmaceutical market.

Acquisition of Labrys Biologics Inc. in the US opens the door for Teva to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.

Teva acquires Auspex, in order to strengthen Teva's core central nervous system franchise for treatment of movement disorders.

Teva establishes a business venture with Takeda, Japan's largest pharmaceutical company, leveraging Teva’s deep marketing expertise, commercial and medical excellence, with Takeda’s leading brand reputation and strong distribution presence in Japan.

Teva acquires Actavis Generics, significantly expanding Teva’s generic product portfolio, R&D capabilities, product pipeline and global operational network.

The same year, Teva acquires Anda Inc, a leading distributor of generic pharmaceuticals in the US. This strategic move enables Teva to improve capabilities and flexibility in order to provide access to more patients throughout the US.

Teva celebrates 120 years since its founding, focused on being a global leader in generic and biopharmaceutical medicines, with a strong innovative portfolio.